<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631458</url>
  </required_header>
  <id_info>
    <org_study_id>MPN-SVT v11; 02/Dec/2013</org_study_id>
    <nct_id>NCT04631458</nct_id>
  </id_info>
  <brief_title>Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis</brief_title>
  <acronym>Mascot</acronym>
  <official_title>A Study Assessing Morbidity and Portal Circulation in Patients With Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Free Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Free Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Myeloproliferative neoplasms are at particular risk for developing arterial and&#xD;
      venous thrombosis, especially thrombosis in the splanchnic venous system. The&#xD;
      patho-physiology and natural history of MPN related SVT is poorly understood and treatment&#xD;
      algorithms vary greatly. This is of considerable importance since the morbidity and mortality&#xD;
      in this group of patients is high. This study aims to observe patients with MPN related SVT&#xD;
      over a period of five years to document their clinical progress. Methods of observation&#xD;
      include clinical assessment, standard investigations and laboratory based research&#xD;
      investigations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Title Morbidity and portal circulation in patients with Myeloproliferative neoplasms&#xD;
      and splanchnic vein thrombosis: Mascot Protocol No. MPN-SVT v11; 02/Dec/2013 Study Design&#xD;
      Prospective observational longitudinal study of patients with MPN related splanchnic vein&#xD;
      thrombosis(study group) and patients with MPN without SVT (control group) Study Participants&#xD;
      Patients with myeloproliferative neoplasms (MPN) and splanchnic vein thrombosis (SVT),&#xD;
      patients with MPN and splenomegaly.&#xD;
&#xD;
      Number of subjects 40 patients Follow-up duration 5 years Study duration January 2014-&#xD;
      January 2019. Primary Objectives 1. To describe morbidity/portal circulation in the patient&#xD;
      group over the 18m from baseline 2. To examine if there are changes in endpoints from&#xD;
      baseline to 18m 3. To compare patients with MPN related SVT and MPN without SVT Secondary&#xD;
      Objectives 1. To describe morbidity/portal circulation in the patient group over 5 years from&#xD;
      baseline 2. To examine if there are changes in endpoints from baseline to 5 years 3. To&#xD;
      assess the impact of treatment including cytoreductive therapy, Janus kinase (JAK) inhibition&#xD;
      and antithrombotic treatment on end points.&#xD;
&#xD;
      4. To assess adequacy of anti-thrombotic agents with reference to recurrence, recanalisation&#xD;
      and extension of splanchnic thrombosis, non-splanchnic thrombotic events and bleeding&#xD;
      frequency.&#xD;
&#xD;
      Exploratory objectives 1. Assess the utility of endothelial colony assay as marker of disease&#xD;
      2. Assess the utility of adhesion molecules as markers of disease&#xD;
&#xD;
      Primary Endpoint Composite end point comprising occurrence or change in morbidity or portal&#xD;
      circulation over 18 months Secondary Endpoint Occurence or change in morbidity or portal&#xD;
      circulation over 3-5 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 12, 2014</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite end point comprising occurrence or change in morbidity or portal circulation over 18 months</measure>
    <time_frame>12-18 months from baseline</time_frame>
    <description>analysed by radiologic investigations and clinical progress</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Occurrence or changes in morbidity over 5 years 2. Occurrence or changes in portal circulation over 5 years</measure>
    <time_frame>5 years from baseline</time_frame>
    <description>analysed by radiologic investigations and clinical progress</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Splanchnic Vein Thrombosis</condition>
  <condition>Splanchnic Venous Thrombosis</condition>
  <condition>Myeloproliferative Disorders</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care.</intervention_name>
    <description>Observational trial.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        as above&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. MPN with SVT between 3 weeks to 5 years of diagnosis of SVT: study arm&#xD;
&#xD;
          2. MPN with palpable splenomegaly or enlarged by Ultrasound: control arm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Age &lt;18 years Patients with SVT without MPN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thrombosis</keyword>
  <keyword>splanchnic</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>TIPSS</keyword>
  <keyword>myeloproliferative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

